Charcot Foot Offloading in Stage 0 Is Associated With Shorter Total Contact Cast Treatment and Lower Risk of Recurrence and Reconstructive Surgery: A Pilot Study.
TL;DR
Offloading in stage 0 CF was associated with shorter TCC treatment, lower risk of a new CF event, and diminished need for reconstructive surgery, and future amputation risk was not affected.
OpenAlex 토픽 ·
Diabetic Foot Ulcer Assessment and Management
Wound Healing and Treatments
Reconstructive Surgery and Microvascular Techniques
【연구 목적】 활성기 샤코 발(Charcot foot)의 가장 초기 단계인 0기(stage 0)는 골절이나 변형 없이 염증 징후만 나타나는 특징이 있다.
- p-value P = 0.001
- p-value P < 0.05
- 연구 설계 cohort study
APA
Johan Schoug, Per Katzman, et al. (2024). Charcot Foot Offloading in Stage 0 Is Associated With Shorter Total Contact Cast Treatment and Lower Risk of Recurrence and Reconstructive Surgery: A Pilot Study.. Diabetes care, 47(2), 252-258. https://doi.org/10.2337/dc23-1063
MLA
Johan Schoug, et al.. "Charcot Foot Offloading in Stage 0 Is Associated With Shorter Total Contact Cast Treatment and Lower Risk of Recurrence and Reconstructive Surgery: A Pilot Study.." Diabetes care, vol. 47, no. 2, 2024, pp. 252-258.
PMID
38032793
Abstract
[OBJECTIVE] Charcot foot (CF) requires prolonged offloading of the affected foot to decrease the risk of deformity. The earliest phase in active CF (stage 0) is characterized by inflammatory signs without established fractures or skeletal deformity. We investigated whether offloading in stage 0 influences duration of total contact casting (TCC), risk of recurrence, and future need for surgery.
[RESEARCH DESIGN AND METHODS] All patients treated for active CF at Skåne University Hospital (Lund, Sweden) between 2006 and 2019 were screened for participation in a retrospective cohort study. CF events of included patients were classified as stage 0 or 1 according to X-ray and MRI reports.
[RESULTS] A total of 183 individuals (median age 61 [interquartile range (IQR) 52-68] years, 37% type 1 diabetes, 62% men) were followed for a median of 7.0 (IQR 3.9-11) years. In 198 analyzed CF events, 74 were treated with offloading in stage 0 and 124 in stage 1. Individuals offloading in stage 0 had significantly shorter TCC duration (median 75 [IQR 51-136] vs. 111.5 [72-158] days; P = 0.001). The difference was sustained when including only MRI-confirmed CF. The risk of developing new ipsilateral CF events >1 year after introduced definitive footwear was lower in those treated with offloading in stage 0 (2.7% vs. 9.7%; P < 0.05). No individual treated with offloading in stage 0 underwent reconstructive surgery, compared with 11 (8.9%) treated with offloading in stage 1 (P < 0.01). Amputation rates were similar.
[CONCLUSIONS] Offloading in stage 0 CF was associated with shorter TCC treatment, lower risk of a new CF event, and diminished need for reconstructive surgery. Future amputation risk was not affected.
[RESEARCH DESIGN AND METHODS] All patients treated for active CF at Skåne University Hospital (Lund, Sweden) between 2006 and 2019 were screened for participation in a retrospective cohort study. CF events of included patients were classified as stage 0 or 1 according to X-ray and MRI reports.
[RESULTS] A total of 183 individuals (median age 61 [interquartile range (IQR) 52-68] years, 37% type 1 diabetes, 62% men) were followed for a median of 7.0 (IQR 3.9-11) years. In 198 analyzed CF events, 74 were treated with offloading in stage 0 and 124 in stage 1. Individuals offloading in stage 0 had significantly shorter TCC duration (median 75 [IQR 51-136] vs. 111.5 [72-158] days; P = 0.001). The difference was sustained when including only MRI-confirmed CF. The risk of developing new ipsilateral CF events >1 year after introduced definitive footwear was lower in those treated with offloading in stage 0 (2.7% vs. 9.7%; P < 0.05). No individual treated with offloading in stage 0 underwent reconstructive surgery, compared with 11 (8.9%) treated with offloading in stage 1 (P < 0.01). Amputation rates were similar.
[CONCLUSIONS] Offloading in stage 0 CF was associated with shorter TCC treatment, lower risk of a new CF event, and diminished need for reconstructive surgery. Future amputation risk was not affected.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | skeletal
|
scispacy | 1 | ||
| 약물 | CF events
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 질환 | Charcot
|
scispacy | 1 | ||
| 질환 | CF (stage 0)
|
scispacy | 1 | ||
| 질환 | fractures
|
C0016658
Fracture
|
scispacy | 1 | |
| 질환 | diabetes
|
C0011847
Diabetes
|
scispacy | 1 | |
| 질환 | MRI-confirmed
|
scispacy | 1 | ||
| 질환 | TCC
→ total contact casting
|
scispacy | 1 | ||
| 기타 | men
|
scispacy | 1 |
MeSH Terms
Male; Humans; Middle Aged; Aged; Female; Diabetic Foot; Pilot Projects; Retrospective Studies; Surgery, Plastic; Foot